Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Completed 21Unknown 4Recruiting 2Active not recruiting 2Not yet recruiting 1No longer available 1Enrolling by invitation 1

Sponsor Class

OTHER 3UNKNOWN 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4

Conditions

Recurrence 7Lymphoma, Non-Hodgkin 6Multiple Myeloma 5Lymphoma, Large B-Cell, Diffuse 4Hodgkin Disease 4Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 2Waldenstrom Macroglobulinemia 1Small Cell Lung Carcinoma 1Neoplasms, Plasma Cell 1Neoplasms, Experimental 1Neoplasms by Histologic Type 1Lymphomatoid Granulomatosis 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, B-Cell 1Leukemia 1Immune System Diseases 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 12Etoposide 10Doxorubicin 9Brentuximab Vedotin 8fludarabine phosphate 7Vinblastine 7Dacarbazine 7Bleomycin 7Vincristine 6Melphalan 6camrelizumab 5Radiotherapy 5Nivolumab 5Mycophenolic Acid 5Decitabine 5pembrolizumab 4Rituximab 4Peripheral Blood Stem Cell Transplantation 4Gemcitabine 4Filgrastim 4Cytarabine 4Cyclosporine 4Busulfan 4Bendamustine Hydrochloride 4ABVD protocol 4Tacrolimus 3Prednisone 3N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3Ifosfamide 3Carboplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Unknown × Hodgkin Disease × Bendamustine Hydrochloride × Clear all
NCT05757466 2023-12-19

Prolgo-HL

St. Petersburg State Pavlov Medical University

Phase 2 Unknown
30 enrolled
Lymphoid

Hodgkin Disease, Recurrence

NCT03315520 2018-05-22

BeEAC-1

State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia

Phase 2 Unknown
100 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin

NCT01412307 2015-08-11

LEBEN

GiovanniPascale

Phase 1/2 Unknown
36 enrolled
Lymphoid

Hodgkin Disease

NCT01884441 2014-01-29

Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients

Istituto Clinico Humanitas

Phase 2 Unknown
59 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡